A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...
PK, safety and acceptability data and practical guidance on the optimal dosing of new more child-friendly formulations of...
Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...
A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...
1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...
